Navigation Links
New Drug Promising Against Tough-to-Treat Kidney Cancer

Axitinib produced good responses in almost half of patients, study found

TUESDAY, Oct. 30 (HealthDay News) -- An experimental drug called axitinib shows promise for treating people with what's known as cytokine-refractory metastatic kidney cancer -- a group of patients who typically have a poor response to drug treatment.

Axitinib is a selective inhibitor of cancer-linked proteins known as vascular endothelial growth factor receptors 1, 2 and 3.

As reported in the November issue of The Lancet Oncology, the phase II study of 52 patients treated with the drug found that 23 patients had complete or partial responses (some of which were long lasting), and 12 of these patients progressed during the study, with a duration of response ranging from four months to 26 months.

The French researchers also found that 22 patients showed stable disease for longer than eight weeks, including 13 patients with stable disease for 24 weeks or longer.

Four patients had early disease progression, and 30 patients had high blood pressure related to the treatment. In general, side effects were manageable and controlled by dose modification or supportive care, the researchers said.

"The objective response and time to progression in our study suggest that axitinib might be a promising drug in the treatment of patients with metastatic renal-cell cancer, although a randomized controlled trial is needed to confirm this finding," study author Olivier Rixe, a professor in the department of medical oncology at the University of Paris, said in a prepared statement.

These findings "suggest that a drug such as axitinib has promise as a second-line treatment in cytokine-refractory metastatic renal-cell carcinoma and might have potential as first-line treatment or in combination with other agents," Dr. W. Marston Linehan of the U.S. National Cancer Institute, wrote in an accompanying comment.

More information

The U.S. National Cancer Institute has more about kidney cancer.

-- Robert Preidt

SOURCE: The Lancet Oncology, news release, Oct. 30, 2007

Copyright©2007 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. PCR emerging as a promising technique for Diagnosing Urinary Tuberculosis
2. Experimental treatment for Ebola Virus Shows promising results in mice
3. Promising Treatment for Diabetes
4. A promising treatment for wart removal
5. Hepatitis shots is promising
6. Life after Bypass not so Promising for Women.
7. Promising cure for West Nile Virus
8. Deadly Diarrhoea Vaccine – Trail Results Promising
9. Novartis MS Drug Shows Promising Results
10. Sunitinib a Promising Agent for Treatment of Renal Cell Cancer
11. Research Ethics Requirements Compromising Quality of Health Research
Post Your Comments:
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, ... Development, has been awarded a contract by the Center for Medicare and Medicaid ... to accelerate the enterprise use of Agile methodologies in a consistent and high ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 million ... by frequent cessation in breathing. Oral appliances can offer significant relief to about ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics (ACMI) will ... during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual ... F. Collen, a pioneer in the field of medical informatics, this prestigious award is ...
(Date:10/12/2017)... PA (PRWEB) , ... October 12, 2017 , ... ... is the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B ... York City on October 11, 2017. , The annual award competition recognizes editorial and ...
(Date:10/12/2017)... ... ... Health Literacy Innovations (HLI), creator of the Health Literacy ... Patient Education Network (CPEN), an independent professional organization that shares best practices in ... , As CPEN’s strategic partner, HLI will help support CPEN members by sharing ...
Breaking Medicine News(10 mins):
(Date:9/18/2017)... KALAMAZOO, Mich. , Sept. 18, 2017 ... , and OptiMed Specialty Pharmacy of Kalamazoo, ... offer a strategic hub service that expedites and streamlines ... personal spirometer, Spiro PD 2.0, and wellness management services.  ... is a medical device used to measure lung function ...
(Date:9/13/2017)... 2017   OrthoAtlanta has been named the official ... Committee (AFHC) for the 2018 College Football Playoff (CFP) National ... Mercedes-Benz Stadium in Atlanta, Georgia . OrthoAtlanta ... In" campaign, participating in many activities leading up to, and ... ...
(Date:9/12/2017)... 2017  Consumer reviews on the independent review site Consumer ... one company for hearing aids, ranking it higher than Miracle ... ... Consumers For Hearing Aids ... an online store that provides high performance, state-of-the-art, German-engineered hearing aids ...
Breaking Medicine Technology: